Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-671 Safety and PK/PD in Healthy Volunteers and PA/MMA Patients
NCT04836494Phase 1Terminated
- Sponsor
- BridgeBio Pharma
- Start
- Mar 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BBP-671 in propionic acidemia (PA) and methylmalonic acidemia (MMA) (6 arms), sponsored by BridgeBio Pharma. Primary endpoints: Incidence of adverse events following administration of BBP-671 at 49 days, BBP-671 concentration dependent change in change from baseline in QTcF at 49 days and 7 more. Started Mar 2021; status: terminated.
02
Drugs
BBP-671
03
Conditions
propionic acidemia (PA)methylmalonic acidemia (MMA)
Beyond the preview
Go deeper on NCT04836494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836494.